Open Access. Powered by Scholars. Published by Universities.®

Law Commons

Open Access. Powered by Scholars. Published by Universities.®

Fordham Law Review

Journal

FDA

Articles 1 - 4 of 4

Full-Text Articles in Law

"A Distinction Without A Difference"?: Bartlett Going Forward, Steven A. Schwartz Oct 2015

"A Distinction Without A Difference"?: Bartlett Going Forward, Steven A. Schwartz

Fordham Law Review

This Note addresses the question of whether federal law preempts state design defect claims against generic drug manufacturers regardless of which test state law uses to determine whether a drug is defective. This issue, arising out of the U.S. Supreme Court's interpretation of preemption jurisprudence and fundamental tort law as stated in Mutual Pharmaceutical Co. v. Bartlett, is significant because it plays a large role in determining to what extent generic drug manufacturers are immune to civil liability arising out of injuries caused by their generic drugs. In an age of rising medical costs and jury awards, both plaintiff …


The Health Act's Fda Defense To Punitive Damages: A Gift To Drug Makers Or To The Public?, Elissa Levy Jan 2006

The Health Act's Fda Defense To Punitive Damages: A Gift To Drug Makers Or To The Public?, Elissa Levy

Fordham Law Review

No abstract provided.


Fda Disclosure Of Safety And Efficacy Data: The Scope Of Section 301(J), Richard S. Fortunato Jan 1984

Fda Disclosure Of Safety And Efficacy Data: The Scope Of Section 301(J), Richard S. Fortunato

Fordham Law Review

No abstract provided.


Fda Disclosure Of Safety And Efficacy Data: The Scope Of Section 301(J), Richard S. Fortunato Jan 1984

Fda Disclosure Of Safety And Efficacy Data: The Scope Of Section 301(J), Richard S. Fortunato

Fordham Law Review

No abstract provided.